It is time to now look at that segment of the population that is not obese but would benefit from losing 10-25 pounds.
Windsor, ON (PRWEB) September 20, 2007
ArtJen Complexus Holdings Corp. (http://www.fbcx.com) today announced that, following the very exciting results of their clinical trial with obese type 2 diabetics and an animal study at the National Institutes of Health, FBCx is now being studied in the USA by a major west-coast university medical center. The largest study to date on the all natural soluble fiber that binds dietary fat will involve overweight but not obese individuals.
"Our earlier study with obese, type 2 diabetics demonstrated significant weight loss when adjusted for changes in diet." said FBCx co-inventor, Dr. Catherine Jen. She continued, "It is time to now look at that segment of the population that is not obese but would benefit from losing 10-25 pounds."
"One of the things that we learned in the first study was that early intervention was very important for a successful outcome." Dr. Joseph Artiss, FBCx co-inventor, continued, "We expect that this study will show FBCx to be an easy and effective aid for losing weight and for lowering elevated levels of blood fats."
Previous FBCx studies have yielded extremely encouraging findings including:
- FBCx is effective at reducing and/or maintaining body weight in patients with type 2 diabetes.
- FBCx lowered both triglyceride and LDL (bad) cholesterol levels in those patients who began the study with elevated triglyceride levels.
- Findings from blood work indicate an increase in insulin sensitivity and therefore a possible delay in the need to institute or the intensity of insulin therapy in type 2 diabetic patients.
- FBCx was shown to bind and remove 9 times its own weight in dietary fat.
- FBCx appears to preferentially bind saturated over unsaturated dietary fats.
- FBCx produced no adverse side effects.
These findings and others have lead to FBCx being referred to as, "the other diet pill" and the "miracle weight loss" pill in media reports and by renowned members of the medical profession.
"We are so convinced of the efficacy of FBCx that we sought out and funded this major study ourselves," said Dr. Artiss. "We fully expect that this study will add considerable understanding and credibility to this amazing fiber."
"I have spent my entire career studying obesity and FBCx works where most others have failed to live up to their hype. We no longer wish to be referred to as 'the other diet pill'," stated Dr. Jen.
About ArtJen Complexus Holdings Corp.
The co-inventors of FBCx are Associate Professor of Pathology Joseph Artiss, Ph.D., FACB and K-L Catherine Jen, Ph.D., Professor and Chair of Nutrition and Food Science, both of Wayne State University in Detroit, MI.
ArtJen Complexus Holdings Corp. is the sole manufacturer of FBCx tablets, an all-natural, patented dietary fiber. FBCx has the very unique ability to bind and remove nine times its own weight in dietary fat, essentially preventing 80 calories from being absorbed per tablet. Taken as directed, six tablets per day (two tablets of FBCx per fat-containing meal) are capable of removing about 50-60% of the calories from a typical North American diet. This facilitates a safe rate of decrease in body weight of about 1-1½ pounds per week.
For additional information, please visit http://www.fbcx.com or call toll free 1-877-4-ARTJEN.